These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 35743091)

  • 41. Epidemiology and potential pathomechanisms of cardiovascular comorbidities in psoriasis: a report from the GRAPPA 2010 annual meeting.
    Boehncke WH
    J Rheumatol; 2012 Feb; 39(2):441-4. PubMed ID: 22298277
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heart disease in psoriasis.
    Kremers HM; McEvoy MT; Dann FJ; Gabriel SE
    J Am Acad Dermatol; 2007 Aug; 57(2):347-54. PubMed ID: 17433490
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives.
    Boehncke WH; Boehncke S
    Curr Rheumatol Rep; 2012 Aug; 14(4):343-8. PubMed ID: 22562431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic Inflammatory Diseases and Atherosclerotic Cardiovascular Disease: Innocent Bystanders or Partners in Crime?
    Hansen PR
    Curr Pharm Des; 2018; 24(3):281-290. PubMed ID: 29318966
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genetic markers for cardiovascular disease in psoriasis: the missing piece.
    Torres T; Chiricozzi A; Chimenti S; Saraceno R
    Mol Diagn Ther; 2014 Feb; 18(1):93-5. PubMed ID: 24078347
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does treatment of psoriasis reduce the risk of cardiovascular disease?
    Churton S; Brown L; Shin TM; Korman NJ
    Drugs; 2014 Feb; 74(2):169-82. PubMed ID: 24420963
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of psoriasis as a systemic disease: what is the evidence?
    Korman NJ
    Br J Dermatol; 2020 Apr; 182(4):840-848. PubMed ID: 31225638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics.
    Weber B; Merola JF; Husni ME; Di Carli M; Berger JS; Garshick MS
    Curr Atheroscler Rep; 2021 Sep; 23(11):67. PubMed ID: 34468875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Subclinical cardiovascular disease in plaque psoriasis: association or causal link?
    Shaharyar S; Warraich H; McEvoy JW; Oni E; Ali SS; Karim A; Jamal O; Blaha MJ; Blumenthal RS; Fialkow J; Cury R; Budoff MJ; Agatston AA; Nasir K
    Atherosclerosis; 2014 Jan; 232(1):72-8. PubMed ID: 24401219
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiometabolic risk in psoriasis: differential effects of biologic agents.
    Kaplan MJ
    Vasc Health Risk Manag; 2008; 4(6):1229-35. PubMed ID: 19337536
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2).
    Menter MA; Mehta NN; Lebwohl MG; Gottlieb AB; Mendelsohn AM; Rozzo SJ; Leonardi C
    J Drugs Dermatol; 2020 Aug; 19(8):703-708. PubMed ID: 32845115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Psoriasis and Metabolic Syndrome--scientific evidence and therapeutic implications.
    Voiculescu VM; Lupu M; Papagheorghe L; Giurcaneanu C; Micu E
    J Med Life; 2014; 7(4):468-71. PubMed ID: 25713604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Integrated approach to comorbidity in patients with psoriasis.Working Group on Psoriasis-associated Comorbidities].
    Daudén E; Castañeda S; Suárez C; García-Campayo J; Blasco AJ; Aguilar MD; Ferrándiz C; Puig L; Sánchez-Carazo JL;
    Actas Dermosifiliogr; 2012 Jan; 103 Suppl 1():1-64. PubMed ID: 22364603
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Psoriasis and Cardiovascular Disease.
    Shahwan KT; Kimball AB
    Med Clin North Am; 2015 Nov; 99(6):1227-42. PubMed ID: 26476250
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chronic Stress-Related Neural Activity Associates With Subclinical Cardiovascular Disease in Psoriasis: A Prospective Cohort Study.
    Goyal A; Dey AK; Chaturvedi A; Elnabawi YA; Aberra TM; Chung JH; Belur AD; Groenendyk JW; Lerman JB; Rivers JP; Rodante JA; Harrington CL; Varghese NJ; Sanda GE; Baumer Y; Sorokin AV; Teague HL; Genovese LD; Natarajan B; Joshi AA; Playford MP; Bluemke DA; Chen MY; Alavi A; Pitman RK; Powell-Wiley TM; Tawakol A; Gelfand JM; Mehta NN
    JACC Cardiovasc Imaging; 2020 Feb; 13(2 Pt 1):465-477. PubMed ID: 30448131
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Psoriasis and cardiovascular comorbidities with emphasis in Asia.
    Chu TW; Tsai TF
    G Ital Dermatol Venereol; 2012 Apr; 147(2):189-202. PubMed ID: 22481582
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Psoriasis and atherosclerosis: Is there a need for novel biomarkers assessing cardiovascular risk?
    Sunbul M; Agirbasli M
    Curr Pharm Des; 2014; 20(4):529-35. PubMed ID: 23565636
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiometabolic comorbidities and the approach to patients with psoriasis.
    Gisondi P; Girolomoni G
    Actas Dermosifiliogr; 2009 Dec; 100 Suppl 2():14-21. PubMed ID: 20096157
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The concept of psoriasis as a systemic inflammation: implications for disease management.
    Reich K
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():3-11. PubMed ID: 22356630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of cardiovascular risk and carotid intima-media thickness in patients with psoriasis.
    Abrahão-Machado ECF; Mendonça JA; Arruda ACBB; Nucci LB; Santos MASD
    An Bras Dermatol; 2020; 95(2):150-157. PubMed ID: 32122693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.